drugset
drugset / Trial / NCT06194214

A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants

NCT06194214 ↗

Phase 1 Completed 16 enrolled Eli Lilly and Company Loxo Oncology, Inc. · collab
Non-randomizedSequentialOpen-labelBasic science

Summary

The main purpose of this study is to evaluate the effect of Pirtobrutinib (LOXO-305) on multiple oral doses of digoxin (P-gp substrate) when administered as single and multiple doses by collecting the blood samples and conducting the blood tests to measure how much digoxin is in the bloodstream and how the body handles and eliminates it in healthy participants. The study will also evaluate the safety and tolerability of Pirtobrutinib. Participants will stay in this study for up to 58 days, including screening.

Timeline

Start
2021-03-11
Primary completion
2021-06-09
Completion
2021-06-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified 0.25 mg Oral
Subject Pirtobrutinib Other / unclassified 200 mg Oral

Indications

No indication recorded.